Recent research focuses on improving the delivery mechanisms of daunorubicin to enhance its efficacy and reduce side effects. Liposomal formulations and targeted delivery systems are being explored to increase the drug's concentration in cancer cells while sparing healthy tissues. Additionally, combining daunorubicin with other therapies, such as immunotherapy and targeted therapy, shows promise in enhancing treatment responses.
